In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

Jien Wei Liu, Lih Shinn Wang, Yu Jen Cheng, Gwo Jong Hsu, Po Liang Lu, Yung Ching Liu, Chih Ming Chen, Chun Ming Lee, Wu Sun, Tsrang Neng Jang, Ping Cherng Chiang, Yin Ching Chuang, Hsiu Chen Lin, Zhi Yuan Shi, Hsiang Chi Kung, Cheng Hua Huang, Shih Ming Tsao, Chin Te Lu, Chun Hsing Liao, Po Ren Hsueh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.

Original languageEnglish
Pages (from-to)S188-S191
JournalInternational Journal of Antimicrobial Agents
Volume32
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Acinetobacter baumannii
Taiwan
Microbial Sensitivity Tests
Anti-Bacterial Agents
Sulbactam
Amikacin
Imipenem
Ciprofloxacin
tigecycline
In Vitro Techniques
Phenotype
Infection

Keywords

  • Acinetobacter baumannii
  • Antibacterial drug resistance
  • Taiwan
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. / Liu, Jien Wei; Wang, Lih Shinn; Cheng, Yu Jen; Hsu, Gwo Jong; Lu, Po Liang; Liu, Yung Ching; Chen, Chih Ming; Lee, Chun Ming; Sun, Wu; Jang, Tsrang Neng; Chiang, Ping Cherng; Chuang, Yin Ching; Lin, Hsiu Chen; Shi, Zhi Yuan; Kung, Hsiang Chi; Huang, Cheng Hua; Tsao, Shih Ming; Lu, Chin Te; Liao, Chun Hsing; Hsueh, Po Ren.

In: International Journal of Antimicrobial Agents, Vol. 32, No. SUPPL. 3, 11.2008, p. S188-S191.

Research output: Contribution to journalArticle

Liu, JW, Wang, LS, Cheng, YJ, Hsu, GJ, Lu, PL, Liu, YC, Chen, CM, Lee, CM, Sun, W, Jang, TN, Chiang, PC, Chuang, YC, Lin, HC, Shi, ZY, Kung, HC, Huang, CH, Tsao, SM, Lu, CT, Liao, CH & Hsueh, PR 2008, 'In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan', International Journal of Antimicrobial Agents, vol. 32, no. SUPPL. 3, pp. S188-S191. https://doi.org/10.1016/S0924-8579(08)70026-8
Liu, Jien Wei ; Wang, Lih Shinn ; Cheng, Yu Jen ; Hsu, Gwo Jong ; Lu, Po Liang ; Liu, Yung Ching ; Chen, Chih Ming ; Lee, Chun Ming ; Sun, Wu ; Jang, Tsrang Neng ; Chiang, Ping Cherng ; Chuang, Yin Ching ; Lin, Hsiu Chen ; Shi, Zhi Yuan ; Kung, Hsiang Chi ; Huang, Cheng Hua ; Tsao, Shih Ming ; Lu, Chin Te ; Liao, Chun Hsing ; Hsueh, Po Ren. / In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. In: International Journal of Antimicrobial Agents. 2008 ; Vol. 32, No. SUPPL. 3. pp. S188-S191.
@article{70063ebf368a41ff878d970b2904c2b1,
title = "In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan",
abstract = "We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44{\%}), ciprofloxacin (75{\%}), amikacin (69{\%}), sulbactam (34{\%}) and all four antibiotics (22{\%}), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71{\%} to 82{\%}. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9{\%} and 93.1{\%} of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.",
keywords = "Acinetobacter baumannii, Antibacterial drug resistance, Taiwan, Tigecycline",
author = "Liu, {Jien Wei} and Wang, {Lih Shinn} and Cheng, {Yu Jen} and Hsu, {Gwo Jong} and Lu, {Po Liang} and Liu, {Yung Ching} and Chen, {Chih Ming} and Lee, {Chun Ming} and Wu Sun and Jang, {Tsrang Neng} and Chiang, {Ping Cherng} and Chuang, {Yin Ching} and Lin, {Hsiu Chen} and Shi, {Zhi Yuan} and Kung, {Hsiang Chi} and Huang, {Cheng Hua} and Tsao, {Shih Ming} and Lu, {Chin Te} and Liao, {Chun Hsing} and Hsueh, {Po Ren}",
year = "2008",
month = "11",
doi = "10.1016/S0924-8579(08)70026-8",
language = "English",
volume = "32",
pages = "S188--S191",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "SUPPL. 3",

}

TY - JOUR

T1 - In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

AU - Liu, Jien Wei

AU - Wang, Lih Shinn

AU - Cheng, Yu Jen

AU - Hsu, Gwo Jong

AU - Lu, Po Liang

AU - Liu, Yung Ching

AU - Chen, Chih Ming

AU - Lee, Chun Ming

AU - Sun, Wu

AU - Jang, Tsrang Neng

AU - Chiang, Ping Cherng

AU - Chuang, Yin Ching

AU - Lin, Hsiu Chen

AU - Shi, Zhi Yuan

AU - Kung, Hsiang Chi

AU - Huang, Cheng Hua

AU - Tsao, Shih Ming

AU - Lu, Chin Te

AU - Liao, Chun Hsing

AU - Hsueh, Po Ren

PY - 2008/11

Y1 - 2008/11

N2 - We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.

AB - We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.

KW - Acinetobacter baumannii

KW - Antibacterial drug resistance

KW - Taiwan

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=55649117054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649117054&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(08)70026-8

DO - 10.1016/S0924-8579(08)70026-8

M3 - Article

VL - 32

SP - S188-S191

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - SUPPL. 3

ER -